File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study
  • Basic View
  • Metadata View
  • XML View
TitleMcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study
 
AuthorsFong, PY1
Xue, WC1
Ngan, HYS1
Chan, KYK1 1
Khoo, US1
Tsao, SW1
Chiu, PM1
Man, LS1
Cheung, ANY1
 
Keywordsc-DNA array
Gestational trophoblastic disease
Hydatidiform mole
Mcl-1
 
Issue Date2005
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
 
CitationCancer, 2005, v. 103 n. 2, p. 268-276 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.20767
 
AbstractBACKGROUND. Hydatidiform moles (HMs) are abnormal pregnancies with a propensity for developing persistent disease in the form of gestational trophoblastic neoplasia (GTN), which requires chemotherapy. In previous studies, the authors demonstrated that low apoptotic activity was correlated with the progression of HM to GTN, and they hypothesized that some apoptosis-related genes may determine this progression. METHODS. The differential expression of apoptotic genes in HMs that subsequently developed into GTN was compared with the same expression in HMs that spontaneously regressed using a human apoptosis array; then, the expression was evaluated with real-time quantitative polymerase chain reaction analysis and immunohistochemistry using 54 clinical samples from patients with HMs who had follow-up data available. RESULTS. Using an apoptosis array, greater expression of Mcl-1, which is an antiapoptotic gene, was detected in HMs that subsequently developed into GTN. It was confirmed that the levels of Mcl-1 RNA expression (P = 0.017) and Mcl-1 protein expression (P < 0.001) in HMs that developed into persistent disease and required chemotherapy were significantly greater compared with the levels in HMs that regressed. Moreover, Mcl-1 immunoreactivity, which was detected predominantly in cytotrophoblasts, was correlated with the apoptotic index, as assessed with M30 cytoDeath immunohistochemistry, which is a good indicator of apoptotic events in the early-stage disease. CONCLUSIONS. The current results demonstrated that Mcl-1, as identified by a cyclic DNA array, may play a role in the pathogenesis of HMs and may have potential as a useful marker for predicting the clinical behavior of HMs. © 2004 American Cancer Society.
 
ISSN0008-543X
2012 Impact Factor: 5.201
2012 SCImago Journal Rankings: 2.407
 
DOIhttp://dx.doi.org/10.1002/cncr.20767
 
ISI Accession Number IDWOS:000226379000008
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorFong, PY
 
dc.contributor.authorXue, WC
 
dc.contributor.authorNgan, HYS
 
dc.contributor.authorChan, KYK
 
dc.contributor.authorKhoo, US
 
dc.contributor.authorTsao, SW
 
dc.contributor.authorChiu, PM
 
dc.contributor.authorMan, LS
 
dc.contributor.authorCheung, ANY
 
dc.date.accessioned2012-05-29T06:12:38Z
 
dc.date.available2012-05-29T06:12:38Z
 
dc.date.issued2005
 
dc.description.abstractBACKGROUND. Hydatidiform moles (HMs) are abnormal pregnancies with a propensity for developing persistent disease in the form of gestational trophoblastic neoplasia (GTN), which requires chemotherapy. In previous studies, the authors demonstrated that low apoptotic activity was correlated with the progression of HM to GTN, and they hypothesized that some apoptosis-related genes may determine this progression. METHODS. The differential expression of apoptotic genes in HMs that subsequently developed into GTN was compared with the same expression in HMs that spontaneously regressed using a human apoptosis array; then, the expression was evaluated with real-time quantitative polymerase chain reaction analysis and immunohistochemistry using 54 clinical samples from patients with HMs who had follow-up data available. RESULTS. Using an apoptosis array, greater expression of Mcl-1, which is an antiapoptotic gene, was detected in HMs that subsequently developed into GTN. It was confirmed that the levels of Mcl-1 RNA expression (P = 0.017) and Mcl-1 protein expression (P < 0.001) in HMs that developed into persistent disease and required chemotherapy were significantly greater compared with the levels in HMs that regressed. Moreover, Mcl-1 immunoreactivity, which was detected predominantly in cytotrophoblasts, was correlated with the apoptotic index, as assessed with M30 cytoDeath immunohistochemistry, which is a good indicator of apoptotic events in the early-stage disease. CONCLUSIONS. The current results demonstrated that Mcl-1, as identified by a cyclic DNA array, may play a role in the pathogenesis of HMs and may have potential as a useful marker for predicting the clinical behavior of HMs. © 2004 American Cancer Society.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationCancer, 2005, v. 103 n. 2, p. 268-276 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.20767
 
dc.identifier.doihttp://dx.doi.org/10.1002/cncr.20767
 
dc.identifier.epage276
 
dc.identifier.hkuros109806
 
dc.identifier.isiWOS:000226379000008
 
dc.identifier.issn0008-543X
2012 Impact Factor: 5.201
2012 SCImago Journal Rankings: 2.407
 
dc.identifier.issue2
 
dc.identifier.pmid15578716
 
dc.identifier.scopuseid_2-s2.0-12344276322
 
dc.identifier.spage268
 
dc.identifier.urihttp://hdl.handle.net/10722/148384
 
dc.identifier.volume103
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
 
dc.publisher.placeUnited States
 
dc.relation.ispartofCancer
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshBase Sequence
 
dc.subject.meshBiopsy, Needle
 
dc.subject.meshCohort Studies
 
dc.subject.meshDna, Complementary - Analysis
 
dc.subject.meshDisease Progression
 
dc.subject.meshFemale
 
dc.subject.meshGene Expression Regulation, Neoplastic
 
dc.subject.meshGestational Trophoblastic Disease - Genetics - Pathology
 
dc.subject.meshHumans
 
dc.subject.meshHydatidiform Mole - Genetics - Pathology
 
dc.subject.meshImmunohistochemistry
 
dc.subject.meshIn Situ Nick-End Labeling
 
dc.subject.meshLogistic Models
 
dc.subject.meshMiddle Aged
 
dc.subject.meshMolecular Sequence Data
 
dc.subject.meshNeoplasm Proteins - Genetics - Metabolism
 
dc.subject.meshPregnancy
 
dc.subject.meshProbability
 
dc.subject.meshPrognosis
 
dc.subject.meshProto-Oncogene Proteins C-Bcl-2 - Genetics - Metabolism
 
dc.subject.meshRna, Neoplasm - Analysis
 
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
 
dc.subject.meshSensitivity And Specificity
 
dc.subject.meshTumor Markers, Biological - Analysis
 
dc.subject.meshUterine Neoplasms - Genetics - Pathology
 
dc.subjectc-DNA array
 
dc.subjectGestational trophoblastic disease
 
dc.subjectHydatidiform mole
 
dc.subjectMcl-1
 
dc.titleMcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fong, PY</contributor.author>
<contributor.author>Xue, WC</contributor.author>
<contributor.author>Ngan, HYS</contributor.author>
<contributor.author>Chan, KYK</contributor.author>
<contributor.author>Khoo, US</contributor.author>
<contributor.author>Tsao, SW</contributor.author>
<contributor.author>Chiu, PM</contributor.author>
<contributor.author>Man, LS</contributor.author>
<contributor.author>Cheung, ANY</contributor.author>
<date.accessioned>2012-05-29T06:12:38Z</date.accessioned>
<date.available>2012-05-29T06:12:38Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Cancer, 2005, v. 103 n. 2, p. 268-276</identifier.citation>
<identifier.issn>0008-543X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/148384</identifier.uri>
<description.abstract>BACKGROUND. Hydatidiform moles (HMs) are abnormal pregnancies with a propensity for developing persistent disease in the form of gestational trophoblastic neoplasia (GTN), which requires chemotherapy. In previous studies, the authors demonstrated that low apoptotic activity was correlated with the progression of HM to GTN, and they hypothesized that some apoptosis-related genes may determine this progression. METHODS. The differential expression of apoptotic genes in HMs that subsequently developed into GTN was compared with the same expression in HMs that spontaneously regressed using a human apoptosis array; then, the expression was evaluated with real-time quantitative polymerase chain reaction analysis and immunohistochemistry using 54 clinical samples from patients with HMs who had follow-up data available. RESULTS. Using an apoptosis array, greater expression of Mcl-1, which is an antiapoptotic gene, was detected in HMs that subsequently developed into GTN. It was confirmed that the levels of Mcl-1 RNA expression (P = 0.017) and Mcl-1 protein expression (P &lt; 0.001) in HMs that developed into persistent disease and required chemotherapy were significantly greater compared with the levels in HMs that regressed. Moreover, Mcl-1 immunoreactivity, which was detected predominantly in cytotrophoblasts, was correlated with the apoptotic index, as assessed with M30 cytoDeath immunohistochemistry, which is a good indicator of apoptotic events in the early-stage disease. CONCLUSIONS. The current results demonstrated that Mcl-1, as identified by a cyclic DNA array, may play a role in the pathogenesis of HMs and may have potential as a useful marker for predicting the clinical behavior of HMs. &#169; 2004 American Cancer Society.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741</publisher>
<relation.ispartof>Cancer</relation.ispartof>
<subject>c-DNA array</subject>
<subject>Gestational trophoblastic disease</subject>
<subject>Hydatidiform mole</subject>
<subject>Mcl-1</subject>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Base Sequence</subject.mesh>
<subject.mesh>Biopsy, Needle</subject.mesh>
<subject.mesh>Cohort Studies</subject.mesh>
<subject.mesh>Dna, Complementary - Analysis</subject.mesh>
<subject.mesh>Disease Progression</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Gene Expression Regulation, Neoplastic</subject.mesh>
<subject.mesh>Gestational Trophoblastic Disease - Genetics - Pathology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Hydatidiform Mole - Genetics - Pathology</subject.mesh>
<subject.mesh>Immunohistochemistry</subject.mesh>
<subject.mesh>In Situ Nick-End Labeling</subject.mesh>
<subject.mesh>Logistic Models</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Molecular Sequence Data</subject.mesh>
<subject.mesh>Neoplasm Proteins - Genetics - Metabolism</subject.mesh>
<subject.mesh>Pregnancy</subject.mesh>
<subject.mesh>Probability</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Proto-Oncogene Proteins C-Bcl-2 - Genetics - Metabolism</subject.mesh>
<subject.mesh>Rna, Neoplasm - Analysis</subject.mesh>
<subject.mesh>Reverse Transcriptase Polymerase Chain Reaction</subject.mesh>
<subject.mesh>Sensitivity And Specificity</subject.mesh>
<subject.mesh>Tumor Markers, Biological - Analysis</subject.mesh>
<subject.mesh>Uterine Neoplasms - Genetics - Pathology</subject.mesh>
<title>Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study</title>
<type>Article</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1002/cncr.20767</identifier.doi>
<identifier.pmid>15578716</identifier.pmid>
<identifier.scopus>eid_2-s2.0-12344276322</identifier.scopus>
<identifier.hkuros>109806</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-12344276322&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>103</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>268</identifier.spage>
<identifier.epage>276</identifier.epage>
<identifier.isi>WOS:000226379000008</identifier.isi>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/148384/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong